Tenaya TherapeuticsTNYA
About: Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Employees: 140
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
6,350% more call options, than puts
Call options by funds: $129K | Put options by funds: $2K
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
8% more funds holding
Funds holding: 88 [Q1] → 95 (+7) [Q2]
0.94% more ownership
Funds ownership: 71.5% [Q1] → 72.44% (+0.94%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
40% less capital invested
Capital invested by funds: $294M [Q1] → $176M (-$117M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Canaccord Genuity Whitney Ijem 25% 1-year accuracy 6 / 24 met price target | 747%upside $16 | Buy Maintained | 18 Oct 2024 |
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 81 / 221 met price target | 852%upside $18 | Buy Reiterated | 18 Oct 2024 |
